Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL1019196

C[C@@H]1CN(C(=O)c2ccc(NC(=O)NC3CCC3)cc2)C[C@H](C)N1Cc1cccc(C(=O)NC(C)(C)C)c1.O=C(O)C(F)(F)F

nearest known ligand 0.40

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.40
KMT2A Q03164 2/20 0.40
GAA P10253 1/20 0.40
MAPT P10636 1/20 0.40
XBP1 P17861 1/20 0.40
MAPK1 P28482 1/20 0.40
USP30 Q70CQ3 1/20 0.40
CYP2D6 P10635 1/20 0.39
CYP2C19 P33261 1/20 0.39
UBE2M P61081 2/20 0.38
DCUN1D1 Q96GG9 2/20 0.38
ACKR3 P25106 4/20 0.38
SLC2A1 P11166 2/20 0.37
PPARA Q07869 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
MEN1 O00255 1/20 0.37
EPHX2 P34913 1/20 0.37
NPY1R P25929 1/20 0.37
OPRK1 P41145 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12955054 0.95 USP30 (0.41) SMN1; SMN2KMT2AGAAMAPTXBP1
Trifluoroacetic Acid SCHEMBL1017954 0.86 SLC2A1 (0.42) KMT2AUBE2MDCUN1D1ACKR3SLC2A1
Trifluoroacetic Acid SCHEMBL1017952 0.86 SLC2A1 (0.42) KMT2AUBE2MDCUN1D1ACKR3SLC2A1
Trifluoroacetic Acid SCHEMBL1021467 0.86 SLC2A1 (0.48) KMT2AUBE2MDCUN1D1ACKR3SLC2A1
SCHEMBL12954974 0.82 DRD2 (0.47) KMT2AUBE2MDCUN1D1ACKR3
SCHEMBL1019198 0.82 SMN1; SMN2 (0.38) SMN1; SMN2KMT2AGAAMAPTXBP1
Hydrochloric Acid SCHEMBL1074147 0.82 ACKR3 (0.46) KMT2AUBE2MDCUN1D1ACKR3MEN1
SCHEMBL13663358 0.81 PKM (0.42) SMN1; SMN2KMT2AMAPTUSP30CYP2D6
SCHEMBL12955051 0.81 ACKR3 (0.42) KMT2AUBE2MDCUN1D1ACKR3
SCHEMBL12954826 0.80 ACKR3 (0.45) KMT2AUBE2MDCUN1D1ACKR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8314091-B2 N-benzyl,N'-arylcarbonylpiperazine derivatives MSD OSS B.V. (NL) 2012-11-20 US disclosed
EP-2190827-B1 N-BENZYL-N'-ARYLCARBONYLPIPERAZINE DERIVATIVES AS LXR MODULATORS ORGANON NV (NL) 2011-01-12 EP disclosed
US-20090264416-A1 N-BENZYL,N'-ARYLCARBONYLPIPERAZINE DERIVATIVES N.V. ORGANON AND PHARMACOPEIA, INC. 2009-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264416-A1 N-BENZYL,N'-ARYLCARBONYLPIPERAZINE DERIVATIVES NPC1L1, NPC1, ABCB11 SMN1; SMN2 4452/4885KMT2A 4268/4885GAA 867/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.